Experimental vaccine displays potential in type 1 diabetes

06/27/2013 | Reuters

Insulin-treated type 1 diabetes patients who received the experimental vaccine TOL-3021 once weekly showed increased C-peptide levels and attained reductions in T-cell rates, according to a study in Science Translational Medicine. The vaccine also helped preserve some remaining beta cells in patients at 12 weeks without side effects, researchers noted.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL